2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2022
Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis
Kanbay M, Yildiz AB, Siriopol D, Vehbi S, Hasbal NB, Kesgin YE, Celayir M, Selcukbiricik F, Covic A, Perazella MA. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology And Nephrology 2022, 55: 1025-1032. PMID: 36282399, DOI: 10.1007/s11255-022-03395-y.Peer-Reviewed Original ResearchConceptsAcute kidney injuryImmune checkpoint inhibitorsSolid organ malignanciesCheckpoint inhibitorsKidney injuryOrgan malignanciesNephrotoxic agentsSingle-center retrospective cohort studyType of ICIBaseline serum creatinine levelAcute interstitial nephritisLocation of malignancyRetrospective cohort studySerum creatinine levelsKidney function recoveryRenal replacement therapyUrinary tract obstructionRisk of mortalityICPI treatmentRenal prognosisTract obstructionCohort studyCreatinine levelsFive patientsInterstitial nephritisDiagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapyThe association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Kanbay M, Copur S, Siriopol D, Yildiz A, Berkkan M, Popa R, Hasbal N, Ortiz A, Perazella M. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Clinical Kidney Journal 2022, 16: 817-826. PMID: 37151409, PMCID: PMC10157786, DOI: 10.1093/ckj/sfac194.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsEffect of AKICheckpoint inhibitorsCancer patientsKidney injuryDevelopment of AKISystematic reviewImmune checkpoint inhibitor therapySevere acute kidney injuryPersistent kidney dysfunctionSevere AKI patientsCheckpoint inhibitor therapyRisk of deathNon-randomized studiesCochrane Library databasesRisk of mortalityNovel therapeutic approachesWeb of ScienceAKI patientsICPI treatmentCause mortalityInhibitor therapyKidney dysfunctionMortality outcomesDrug-Induced Acute Kidney Injury
Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1220-1233. PMID: 35273009, PMCID: PMC9435983, DOI: 10.2215/cjn.11290821.Peer-Reviewed Original ResearchConceptsKidney injuryTubular injuryDrug-induced acute kidney injuryT cell-mediated immune responsesDrug-related kidney injuryCell-mediated immune responsesAcute interstitial nephritisDirect tubular injuryTreatment of AKIAcute kidney injuryAcute tubular injuryIntensive care unitInduction of inflammationAKI riskIntratubular obstructionTubulointerstitial injuryInterstitial nephritisCare unitInflammation leadInjury resultsCommon causeImmune responseHospital wardsProximal tubulesAKIMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2021
The Crystalline Nephropathies
Perazella MA, Herlitz LC. The Crystalline Nephropathies. Kidney International Reports 2021, 6: 2942-2957. PMID: 34901567, PMCID: PMC8640557, DOI: 10.1016/j.ekir.2021.09.003.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseKidney injuryCrystalline nephropathyKidney diseaseCrystal depositionFurther kidney injuryIntrarenal crystal depositionUrinary sediment findingsUrine sediment examinationTubular obstructionHistologic findingsPathologic aspectsNephropathyClinical standpointInjuryTubular luminaSediment examinationFluid physiologyIdentification of crystalsCliniciansDiseaseIndirect cytotoxicityBiopsyInflammationImmunotherapy-Related Acute Kidney Injury
Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-Related Acute Kidney Injury. Advances In Kidney Disease And Health 2021, 28: 429-437.e1. PMID: 35190109, DOI: 10.1053/j.ackd.2021.07.006.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyEffective immune checkpoint inhibitorsAcute kidney injuryImmune checkpoint inhibitorsHigh-dose interleukinNumerous clinical trialsT-cell therapyField of oncologyCheckpoint inhibitorsKidney injuryGeneration immunotherapiesClinical trialsClinical practiceImmunotherapyImmune systemAdverse effectsNephrotoxicityInterleukinPathophysiologyInjuryTherapyCancerOncologyTrialsCheckpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
Perazella MA, Sprangers B. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. Clinical Kidney Journal 2021, 14: 1301-1306. PMID: 33970161, PMCID: PMC8087122, DOI: 10.1093/ckj/sfab052.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsAcute tubulointerstitial nephritisKidney biopsyImmune-related adverse eventsVall d'Hebron University HospitalSingle-center studyNoninvasive diagnostic markerEvidence-based recommendationsAKI patientsICI rechallengeNephrology servicesCheckpoint inhibitorsICI treatmentKidney injuryAdverse eventsTubulointerstitial nephritisNonhematologic malignanciesUniversity HospitalTreatment protocolClinical practicePatientsOptimal managementDiagnostic markerCancer treatmentPARP inhibitors and the Kidney
Deshpande P, Perazella M, Jhaveri K. PARP inhibitors and the Kidney. Journal Of Onco-Nephrology 2021, 5: 42-47. DOI: 10.1177/2399369320987090.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseIschemic acute kidney injuryEnd-stage kidney diseaseKidney diseaseSepsis-related acute kidney injuryAdvanced chronic kidney diseasePARP inhibitorsPoly (ADP-ribose) polymeraseIncrease serum creatinineUse of PARPisBreast cancer gene mutationsStage kidney diseaseAnti-cancer effectsCancer gene mutationsSafe dosingKidney injurySerum creatinineKidney functionKidney effectsClinical trialsLong-term effectsAnimal modelsCellular necrosisPARPis
2020
Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 298: 202903. PMID: 33170103, DOI: 10.1148/radiol.2020202903.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaSimultaneous joint publicationKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskUse of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 3: 142-150. PMID: 33604544, PMCID: PMC7873723, DOI: 10.1016/j.xkme.2020.10.001.Peer-Reviewed Original ResearchNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskFibrosisUrine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete dataOnconephrology: The intersections between the kidney and cancer
Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA A Cancer Journal For Clinicians 2020, 71: 47-77. PMID: 32853404, DOI: 10.3322/caac.21636.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseDrug-induced nephrotoxicityKidney diseaseElectrolyte disordersAcute kidney injuryStem cell transplantationParaneoplastic glomerulonephritisKidney injuryCell transplantationTherapeutic regimensCollaborative careCancerDiseasePatientsOnconephrologyNew subspecialtySpecific training programsNephrotoxicityDisordersTraining programGlomerulonephritisRegimensNephrologistsTransplantationOncologistsNSAIDs in CKD: Are They Safe?
Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? American Journal Of Kidney Diseases 2020, 76: 546-557. PMID: 32479922, DOI: 10.1053/j.ajkd.2020.03.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsChronic kidney diseaseGlomerular filtration rateFiltration rateRisk factorsHigh pain burdenAcute kidney injuryManagement of painAnti-inflammatory drugsCKD populationNSAID useKidney injuryPain burdenPain controlHeart failureComorbid conditionsElectrolyte derangementsKidney diseaseSafety dataDrug effectsPatientsIndividualized basisDrug metabolismProgressive lossCautious useImmune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann SM, Perazella MA. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney International Reports 2020, 5: 1139-1148. PMID: 32775813, PMCID: PMC7403510, DOI: 10.1016/j.ekir.2020.04.018.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAcute kidney injuryCheckpoint inhibitorsAdverse renal effectsAdverse renal eventsSubset of patientsPotential risk factorsAcute rejectionRenal eventsKidney injuryRenal effectsTransplant populationRenal toxicityRisk factorsBetter outcomesPatientsNephrotoxicityCliniciansCancer therapyCancerRecent studiesInhibitorsCurrent informationComplicationsProvidersKidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.
Perazella M. Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary. Kidney360 2020, 1: 166-168. PMID: 35378019, PMCID: PMC8809261, DOI: 10.34067/kid.0001072019.Peer-Reviewed Original ResearchNomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communicationSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressureUse of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 2: 85-93. PMID: 33015613, PMCID: PMC7525144, DOI: 10.1016/j.xkme.2020.01.001.Peer-Reviewed Original ResearchAcute kidney injuryGlomerular filtration rateContrast mediumFiltration rateContrast-associated acute kidney injuryContrast-induced acute kidney injuryIntravenous normal salineReduced kidney functionSevere kidney diseaseNational Kidney FoundationIodinated Contrast MediaHigh-risk circumstancesCI-AKIKidney injuryMaintenance dialysisKidney functionKidney diseaseOrdering clinicianNormal salineConsensus statementKidney FoundationTreatment responseAmerican CollegePatientsControl group